

25th January, 2023

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001 (BSE Scrip Code: 500420) The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2022

The Presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31<sup>st</sup> December, 2022 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a

\_\_\_\_\_



Q3 FY 2022-23

Revenues: Summary



## **Revenue: Summary**

Revenues (Rs cr)	Q3 FY23	Q3 FY22	Gr%
India	1,259	1,072	17%
United States	291	235	24%
Germany	241	237	1%
Brazil	248	182	36%
Other countries	291	227	28%
Others	160	155	3%
Total	2,491	2,108	18%

